drugset / Trial / NCT04619706
Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will measure the effect of FSD201 (ultramicronized PEA) + SoC vs placebo + SoC on Day 28, on disease progression in the confirmed coronavirus disease 2019 (COVID-19) patient population.
Timeline
- Start
- 2020-12-14
- Primary completion
- 2021-08-24
- Completion
- 2021-08-24
Outcome
Outcome not reported
Stopped (Enrollment): “Difficulties recruiting new subjects”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palmidrol | Small molecule | 600 mg | Oral |
| Subject | Palmidrol | Small molecule | 1200 mg | Oral |